Pfizer claims first-line success for Tukysa in breast cancer Phase 3 trialnews2025-10-14T18:22:10+00:00October 14th, 2025|Endpoints News|
Moderna previews cancer antigen therapy in melanoma ahead of ESMOnews2025-10-13T15:29:30+00:00October 13th, 2025|Endpoints News|
Tvardi’s stock crashes as STAT3 drug fails Phase 2 after dropouts from side effectsnews2025-10-13T14:15:55+00:00October 13th, 2025|Endpoints News|
Gilead, Arcus’ TIGIT approach exceeds two years of median survival in Phase 2 gastric cancer trialnews2025-10-13T11:19:29+00:00October 13th, 2025|Endpoints News|
Novo Nordisk quits cell therapy as restructure continuesnews2025-10-13T11:05:02+00:00October 13th, 2025|Endpoints News|
Regeneron heads to FDA to seek approval for hearing loss gene therapynews2025-10-13T09:02:48+00:00October 13th, 2025|Endpoints News|
AstraZeneca strikes pricing deal with Trumpnews2025-10-10T22:21:21+00:00October 10th, 2025|Endpoints News|
New study suggests patients with anti-AAV antibodies may still receive gene therapynews2025-10-10T18:47:55+00:00October 10th, 2025|Endpoints News|
Biopharma is wagering billions of dollars that CAR-T therapy can be easier. Will it work this time?news2025-10-10T15:37:23+00:00October 10th, 2025|Endpoints News|
Cabaletta Bio says small number of autoimmune patients responded to its CAR-T without toxic preconditioningnews2025-10-10T14:35:34+00:00October 10th, 2025|Endpoints News|
